Management and Board of Directors
Chris Taves was appointed Chief Operating Officer, BMO Capital Markets in January 2018. In this role, he has oversight of all balance sheet and risk taking activity, as well as regulatory, compliance, and operational functions to ensure they are optimized to satisfy client needs and BMO FG requirements.
Mr. Taves brings over 20 years of customer facing experience covering corporate and institutional clients across a wide range of products, including derivatives, investments, and corporate finance, working closely with I&CB and all areas within Trading Products. Since joining BMO in 2009, he has taken on broader mandates within the Trading Products team, most recently as Co-Head of Global Trading Products.
Mr. Taves is part of the BMO Capital Markets Operating and Executive Committees, the board of BMO Capital Market’s US broker-dealer – BMO Capital Markets Corp., the board of BMO China, and various other leadership committees within BMO Capital Markets and BMO Financial Group.
Mr. Taves holds an MBA from the Ivey School of Business at the University of Western Ontario, a Mathematics degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a member of the United Way Toronto and York Region Major Individual Giving Cabinet and a Director on the board of Armagh, a second-stage housing program for abused women, Operating and Executive committees.
Chris Taves was appointed Chief Operating Officer, BMO Capital Markets in January 2018. In this role, he has oversight of all balance sheet and risk taking activity, as well as regulatory, compliance, and operational functions to ensure they are optimized to satisfy client needs and BMO FG requirements.
Mr. Taves brings over 20 years of customer facing experience covering corporate and institutional clients across a wide range of products, including derivatives, investments, and corporate finance, working closely with I&CB and all areas within Trading Products. Since joining BMO in 2009, he has taken on broader mandates within the Trading Products team, most recently as Co-Head of Global Trading Products.
Mr. Taves is part of the BMO Capital Markets Operating and Executive Committees, the board of BMO Capital Market’s US broker-dealer – BMO Capital Markets Corp., the board of BMO China, and various other leadership committees within BMO Capital Markets and BMO Financial Group.
Mr. Taves holds an MBA from the Ivey School of Business at the University of Western Ontario, a Mathematics degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a member of the United Way Toronto and York Region Major Individual Giving Cabinet and a Director on the board of Armagh, a second-stage housing program for abused women, Operating and Executive committees.
David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.
David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.
David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.
David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.
Shelley is the former President and CEO of Nestlé Canada and a consumer packaged goods industry top executive with an outstanding track record of success. Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion. She began her career at General Mills Canada in 1985 and was named one of Canada’s Most Powerful Women by the Women’s Executive Network (WXN) in 2015, 2016 and 2018. Ms. Martin is a member of the Advisory Board of Moosehead Breweries as well as Crosby Molasses, and is a Director of Vineland Research and Innovation Centre, a leader in horticultural research and innovation. From 2016 to 2018, she served as Board Chair of Food & Consumer Products of Canada (FCPC), which represents more than 100 food, beverage, and consumer product manufacturers of all sizes. From 2013 to 2018, she was a Director of The Grocery Foundation, a not-for-profit organization that has raised over $90 million for student nutrition programs. Ms. Martin is a graduate of Wilfrid Laurier University (Bachelor of Business Administration) and earned the Institute of Corporate Directors ICD. D designation in 2016.
Shelley is the former President and CEO of Nestlé Canada and a consumer packaged goods industry top executive with an outstanding track record of success. Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion. She began her career at General Mills Canada in 1985 and was named one of Canada’s Most Powerful Women by the Women’s Executive Network (WXN) in 2015, 2016 and 2018. Ms. Martin is a member of the Advisory Board of Moosehead Breweries as well as Crosby Molasses, and is a Director of Vineland Research and Innovation Centre, a leader in horticultural research and innovation. From 2016 to 2018, she served as Board Chair of Food & Consumer Products of Canada (FCPC), which represents more than 100 food, beverage, and consumer product manufacturers of all sizes. From 2013 to 2018, she was a Director of The Grocery Foundation, a not-for-profit organization that has raised over $90 million for student nutrition programs. Ms. Martin is a graduate of Wilfrid Laurier University (Bachelor of Business Administration) and earned the Institute of Corporate Directors ICD. D designation in 2016.
Mr. Halyk has 35 years of pharmaceutical industry experience including 33 years with Johnson & Johnson. Among his many career highlights, he served as: Vice-President, Sales and Marketing and a member of the Janssen Management Board with responsibility for innovations in direct-to-consumer advertising, patient education and sales force automation; Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.; and from 2006 until his retirement in 2019 as the President of Janssen Inc. (Canada) where under his leadership, the company became the largest pharmaceutical company in Canada. During his tenure, his accomplishments included, bringing innovative products, services and solutions to market along with new technologies and treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, cardiovascular and metabolism and pulmonary hypertension. Mr. Halyk holds an Honours Business Administration degree from Ivey Business School at Western University. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies (now named Innovative Medicines Canada) from 2012 until 2013. Before joining Johnson & Johnson, Mr. Halyk worked for pharmaceutical company Warner-Lambert in Toronto.
Mr. Halyk has 35 years of pharmaceutical industry experience including 33 years with Johnson & Johnson. Among his many career highlights, he served as: Vice-President, Sales and Marketing and a member of the Janssen Management Board with responsibility for innovations in direct-to-consumer advertising, patient education and sales force automation; Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.; and from 2006 until his retirement in 2019 as the President of Janssen Inc. (Canada) where under his leadership, the company became the largest pharmaceutical company in Canada. During his tenure, his accomplishments included, bringing innovative products, services and solutions to market along with new technologies and treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, cardiovascular and metabolism and pulmonary hypertension. Mr. Halyk holds an Honours Business Administration degree from Ivey Business School at Western University. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies (now named Innovative Medicines Canada) from 2012 until 2013. Before joining Johnson & Johnson, Mr. Halyk worked for pharmaceutical company Warner-Lambert in Toronto.
Dr. Michael Bumby has been appointed to the MediPharm Labs Board of Directors, effective April 1, 2023. Michael served as the Chief Financial Officer of VIVO for over 5 years prior to MediPharm Labs acquiring VIVO Cannabis. Michael has over 20 years of experience in pharmaceuticals with more than 10 years spent internationally with Eli Lilly. He has held previous CFO roles with multiple, NASDAQ and TSX listed public Canadian biotech companies.
Dr. Michael Bumby has been appointed to the MediPharm Labs Board of Directors, effective April 1, 2023. Michael served as the Chief Financial Officer of VIVO for over 5 years prior to MediPharm Labs acquiring VIVO Cannabis. Michael has over 20 years of experience in pharmaceuticals with more than 10 years spent internationally with Eli Lilly. He has held previous CFO roles with multiple, NASDAQ and TSX listed public Canadian biotech companies.
Stock Data
Stock Quote
Medipharm Labs Corp
Toronto Stock Exchange: LABS:CA
Detailed Information
Stock Quote
Medipharm Labs Corp
OTCQB Marketplace: MEDIF:US
Detailed Information
Stock Quote
Medipharm Labs Corp
Berlin: MLZ:BE
Detailed Information
Firm
Analysts
All analyst coverage is conducted by third parties. Please note that any opinions, estimates or forecasts regarding MediPharm Labs' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MediPharm Labs or its management. MediPharm Labs does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by MediPharm Labs.
Sedar
Corporate Governance
The Board of Directors of MediPharm Labs Corp. (the “Company”) sets high standards for the Company’s service providers, employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
and Nomination